Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230

Restoring function in exhausted CD8 T cells during chronic viral infection

Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,621

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199

Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Sharma, P., Retz, M. M., Siefker-Radtke, A. O., Baron, A. D., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D. A., Grimm, M., Sergio Bracarda, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,758

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,590

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452

PD-L1 Expression in Triple-Negative Breast Cancer

Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,420

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Balar, A. V., Castellano, D., O’Donnell, P. H., Grivas, P. D., Vuky, J., Powles, T. B., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,351

Combination cancer immunotherapy and new immunomodulatory targets

Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger‐Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D. A., Vennapusa, B., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,287

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,268

PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma

Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Loi, S., Michiels, S., Salgado, R., Sirtaine, N., José, V., Fumagalli, D., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,254

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Schachter, J., Ribas, A., Long, G. V., Arance, A. M., Grob, J., Mortier, L., DAUD, A. I., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,251

The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling

Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249

SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation

Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,193

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D. V. T., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,125

Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation

Salomon, B. L., & Bluestone, J. A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.225 · Cited by 1,001

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P. A., Johnson, N. A., Brice, P., Radford, J. A., Ribrag, V., Molin, D. L., Vassilakopoulos, T. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1316 · Cited by 991

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Younes, A., Santoro, A., Shipp, M. A., Zinzani, P. L., Timmerman, J. M., Ansell, S. M., Armand, P. A., Fanale, M. A., Ratanatharathorn, V., Kuruvilla, J. G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30167-x · Cited by 933

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869

Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer

Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1051 · Cited by 808

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Dirix, L. Y., Takács, I., Jérusalem, G., Nikolinakos, P. G., Arkenau, H., Forero, A., Boccia, R. V., Lippman, M. E., Somer, R. A., Šmakal, M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 762

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Sharma, P., Callahan, M. K., Bono, P., Kim, J. W., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 681

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Armand, P. A., Shipp, M. A., Ribrag, V., Michot, J., Zinzani, P. L., Kuruvilla, J. G., Snyder, E., Ricart, A. D., Balakumaran, A., Rose, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3467 · Cited by 675

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

Bauml, J. M., Seiwert, T. Y., Pfister, D. G., Worden, F. P., Liu, S. V., Gilbert, J., Saba, N. F., Weiss, J., Wirth, L. J., Sukari, A. W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1524 · Cited by 664

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Perez‐Gracia, J. L., & Haanen, J. B. A. G. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3973 · Cited by 641

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. M., Seiwert, T. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1761 · Cited by 594

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

Hu‐Lieskovan, S., Mok, S., Moreno, B. H., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comı́n-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 576

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

McDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 560

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Frenel, J., Tourneau, C. L., O’Neil, B. H., Ott, P. A., Piha-Paul, S. A., Gomez‐Roca, C., van Brummelen, E. M. J., Rugo, H. S., Thomas, S., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5471 · Cited by 537

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

Gatalica, Z., Snyder, C., Maney, T., Ghazalpour, A., Holterman, D. A., Xiao, N., Overberg, P., Rose, I., Basu, G. D., Vranić, S., et al. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0654 · Cited by 531

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

Ott, P. A., Élez, E., Hiret, S., Kim, D., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 521

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Ott, P. A., Bang, Y., Berton-Rigaud, D., Élez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I. J., Mehnert, J. M., Aung, K. L., Lopez, J. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5952 · Cited by 512

PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase

Kwong, Y., Chan, T. S. Y., Tan, D. C. L., Kim, S. J., Poon, L. M., Mow, B. M. F., Khong, P., Loong, F., Au-Yeung, R. K. H., Iqbal, J., et al. (2017) · Blood · doi:10.1182/blood-2016-12-756841 · Cited by 502

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

Alley, E. W., Lopez, J. S., Santoro, A., Morosky, A., Saraf, S., Piperdi, B., & van Brummelen, E. M. J. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30169-9 · Cited by 491

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

Hsu, C., Lee, S., Ejadi, S., Even, C., Cohen, R. B., Tourneau, C. L., Mehnert, J. M., Algazi, A. P., van Brummelen, E. M. J., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.3675 · Cited by 471

Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1

Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 422

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

Morris, V. K., Salem, M. E., Nimeiri, H. S., Iqbal, S., Singh, P. P., Ciombor, K. K., Polite, B. N., Deming, D. A., Chan, E. W., Wade, J. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30104-3 · Cited by 409

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Peters, S., Gettinger, S. N., Johnson, M. L., Janne, P. A., Garassino, M. C., Christoph, D. C., Toh, C., Rizvi, N. A., Chaft, J. E., Carcereny, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9476 · Cited by 401

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Kudo, T., Hamamoto, Y., Kato, K., Ura, T., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Satoh, T., Iwasa, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30181-x · Cited by 384

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

Liu, W. M., Fowler, D. W., Smith, P., & Dalgleish, A. G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605465 · Cited by 362

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

Atefi, M. S., Avramis, E. V., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D. S., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 344

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer

Webb, J. R., Milne, K., Kroeger, D. R., & Nelson, B. H. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.03.008 · Cited by 340

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

Pillai, R. N., Behera, M., Owonikoko, T. K., Kamphorst, A. O., Pakkala, S., Belani, C. P., Khuri, F. R., Ahmed, R., & Ramalingam, S. S. (2017) · Cancer · doi:10.1002/cncr.31043 · Cited by 337

OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

Reardon, D. A., Omuro, A., Brandes, A. A., Rieger, J., Wick, A., Sepulveda, J., Phuphanich, S., de Souza, P., Ahluwalia, M. S., Lim, M., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox036.071 · Cited by 325

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Herrera, A. F., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Ansell, S. M., Moskowitz, C. H., Fenton, K., et al. (2017) · Blood · doi:10.1182/blood-2017-10-811224 · Cited by 322

T cell anergy and costimulation

Appleman, L. J., & Boussiotis, V. A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00009.x · Cited by 315

Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis

Nishijima, T. F., Shachar, S. S., Nyrop, K. A., & Muss, H. B. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0419 · Cited by 307

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

Necchi, A., Joseph, R. W., Loriot, Y., Hoffman-Censits, J. H., Perez‐Gracia, J. L., Petrylak, D. P., Derleth, C. L., Tayama, D., Zhu, Q., Ding, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx518 · Cited by 302

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

O’Neil, B. H., Wallmark, J. M., Lorente, D., Élez, E., Raimbourg, J., Gomez‐Roca, C., Ejadi, S., Piha-Paul, S. A., Stein, M. N., Razak, A. R. A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189848 · Cited by 299

PD-1 deficiency results in the development of fatal myocarditis in MRL mice

Wang, J., Okazaki, I., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., Hiai, H., Honjo, T., & Okazaki, T. (2010) · International Immunology · doi:10.1093/intimm/dxq026 · Cited by 268

Developmentally regulated expression of the PD-1 protein on the surface of double-negative(CD4–CD8–) thymocytes

Nishimura, H., Agata, Y., Kawasaki, A., Sato, M., Imamura, S., Minato, N., Yagita∥, H., Nakano, T., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.773 · Cited by 261

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Ott, P. A., Piha-Paul, S. A., Münster, P. N., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., Gomez‐Roca, C., Ejadi, S., Stein, M. N., Chan, E. W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx029 · Cited by 259

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

Lee, J.-M., Cimino‐Mathews, A., Peer, C. J., Zimmer, A. S., Lipkowitz, S., Annunziata, C. M., Cao, L., Harrell, M. I., Swisher, E. M., Houston, N. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1340 · Cited by 243

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

Escudier, B. J., Motzer, R. J., Sharma, P., Wagstaff, J., Plimack, E. R., Hammers, H. J., Donskov, F. N., Gurney, H., Sosman, J. A., Zalewski, P. G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.037 · Cited by 237

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

Amin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Knox, J. J., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5010 · Cited by 233

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

Ahn, M., Yang, J. C., Yu, H. A., Saka, H., Ramalingam, S., Goto, K., Kim, S., Yang, L., Walding, A., & Oxnard, G. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30246-5 · Cited by 233

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

Ben‐Ami, E., Barysauskas, C. M., Solomon, S., Tahlil, K., Malley, R., Hohos, M., Polson, K., Loucks, M., Severgnini, M., Patel, T., et al. (2017) · Cancer · doi:10.1002/cncr.30738 · Cited by 231

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

Weiss, G. J., Blaydorn, L., Beck, J., Bornemann-Kolatzki, K., Urnovitz, H. B., Schütz, E., & Khemka, V. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0525-1 · Cited by 218

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

Lázár‐Molnár, E., Yan, Q., Cao, E., Ramagopal, U. A., Nathenson, S. G., & Almo, S. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804453105 · Cited by 207

Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.

Nanda, R., Liu, M., Yau, C. S. F., Asare, S. M., Hylton, N., Veer, L. V., Perlmutter, J., Wallace, A. M., Chien, A. J., Forero, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.506 · Cited by 204

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Li, X., Cheng, Y., Zhang, M., Yan, J., Li, L., Fu, X., Zhang, X., Chang, Y., Sun, Z., Yu, H., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0559-7 · Cited by 203

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Badros, A., Hyjek, E., Ma, N., Lesokhin, A., Dogan, A., Rapoport, A. P., Kocoglu, M., Lederer, E., Philip, S., Milliron, T., et al. (2017) · Blood · doi:10.1182/blood-2017-03-775122 · Cited by 197

Exomics and immunogenics

Champiat, S., Ferté, C., Lebel‐Binay, S., Eggermont, A. M. M., & Soria, J. (2014) · OncoImmunology · doi:10.4161/onci.27817 · Cited by 195

Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy

Zhang, P., Ma, Y., Lv, C., Huang, M., Li, M., Dong, B., Liu, X., An, G., Zhang, W., Zhang, J., et al. (2016) · Cancer Science · doi:10.1111/cas.13072 · Cited by 182

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Spigel, D. R., Schrock, A. B., Fabrizio, D. A., Frampton, G. M., Sun, J., He, J., Gowen, K. A., Johnson, M. L., Bauer, T. M., Kalemkerian, G. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9017 · Cited by 176

KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.

Fuchs, C. S., Doi, T., Jang, R. W.-J., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4003 · Cited by 173

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).

Hamid, O., Sosman, J. A., Lawrence, D. P., Sullivan, R. J., Ibrahim, N., Kluger, H. M., Boasberg, P. D., Flaherty, K. T., Hwu, P., Ballinger, M. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.9010 · Cited by 170

Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).

Tabernero, J. M., Melero, I., Ros, W., Argilés, G., Marabelle, A., Rodriguez-Ruiz, M. E., Albanell, J., Calvo, E., Moreno, V., Cleary, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3002 · Cited by 170

Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.

Kelley, R. K., Abou‐Alfa, G. K., Bendell, J. C., Kim, T., Borad, M. J., Yong, W. P., Morse, M. A., Kang, Y., Rebelatto, M. C., Makowsky, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4073 · Cited by 167

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

Passiglia, F., Bronte, G., Bazan, V., Natoli, C., Rizzo, S., Galvano, A., Listì, A., Cicero, G., Rolfo, C. D., Santini, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7582 · Cited by 166

Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab

Santin, A. D., Bellone, S., Buza, N., Choi, J., Schwartz, P. E., Schlessinger, J., & Lifton, R. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1031 · Cited by 161

Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)

Topalian, S. L., Bhatia, S., Hollebecque, A., Awada, A. H., de Boer, J. P., Kudchadkar, R. R., Gonçalvès, A., Delord, J., Martens, U. M., López-Picazo, J. M., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct074 · Cited by 150

Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.

Disis, M. L., Patel, M. R., Pant, S., Hamilton, E. P., Lockhart, A. C., Kelly, K. L., Beck, J. T., Gordon, M. S., Weiss, G. J., Taylor, M. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.5533 · Cited by 143

Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.

Overman, M. J., Kopetz, S., McDermott, R., Leach, J., Lonardi, S., Lenz, H., Morse, M. A., Desai, J., Hill, A., Axelson, M. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3501 · Cited by 142

A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study

Planchard, D., Yokoi, T., McCleod, M., Fischer, J. R., Kim, Y., Ballas, M. S., Shi, K., & Soria, J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.003 · Cited by 130

Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

Adams, S., Diamond, J. R., Hamilton, E. P., Pohlmann, P. R., Tolaney, S. M., Molinero, L. L., He, X., Waterkamp, D., Funke, R. P., & Powderly, J. D. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.1009 · Cited by 127

Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.

Diaz, L. A., Marabelle, A., Delord, J., Shapira‐Frommer, R., Geva, R., Peled, N., Kim, T. W., André, T., Cutsem, E. V., Guimbaud, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3071 · Cited by 125

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer

Petrylak, D. P., Powles, T. B., Joaquim Bellmunt, B., Braiteh, F., Loriot, Y., Morales‐Barrera, R., Burris, H. A., Kim, J. W., Ding, B., Kaiser, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5440 · Cited by 119

Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.

Kang, Y., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., Yoshikawa, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.2 · Cited by 107

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

Bendell, J. C., Powderly, J. D., Lieu, C. H., Eckhardt, S. G., Hurwitz, H. I., Höchster, H. S., Murphy, J. E., Funke, R. P., Rossi, C., Wallin, J. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.704 · Cited by 101

An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.

Hollebecque, A., Meyer, T., Moore, K. N., Machiels, J., Grève, J. D., López-Picazo, J. M., Oaknin, A., Kerger, J. N., Boni, V., Evans, T. R. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5504 · Cited by 98

Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Cohen, E. E. W., Harrington, K. J., Tourneau, C. L., Dinis, J., Licitra, L. F., Ahn, M.-J., Soria, A., Machiels, J.-P., Mach, N., Mehra, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.040 · Cited by 91

CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups

Escudier, B. J., Tannir, N. M., McDermott, D. F., Frontera, O. A., Melichar, B., Plimack, E. R., Barthélémy, P., George, S., Neiman, V., Porta, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.029 · Cited by 89

Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.

Crocenzi, T. S., El-Khoueiry, A. B., Yau, T. C., Melero, I., Sangro, B., Kudo, M., Hsu, C., Trojan, J., Kim, T., Choo, S.-P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4013 · Cited by 87

Challenges and prospects of immunotherapy as cancer treatment

Rescigno, M., Avogadri, F., & Curigliano, G. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.003 · Cited by 84

A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.

Shahda, S., Noonan, A. M., Bekaii‐Saab, T., O’Neil, B. H., Sehdev, A., Shaib, W. L., Helft, P. R., Loehrer, P. J., Tong, Y., Liu, Z., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3541 · Cited by 76

IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).

Atkins, M. B., McDermott, D. F., Powles, T. B., Motzer, R. J., Rini, B. I., Fong, L. H., Joseph, R. W., Pal, S. K., Sznol, M., Hainsworth, J. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4505 · Cited by 75

KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.

Bang, Y., Muro, K., Fuchs, C. S., Golan, T., Geva, R., Hara, H., Jalal, S. I., Borg, C., Doi, T., Wainberg, Z. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4012 · Cited by 73

Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.

Janjigian, Y. Y., Ott, P. A., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Peltola, K. J., Jaeger, D., Evans, T. R. J., de Braud, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4014 · Cited by 71

A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).

McDermott, D. F., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B. J., Fong, L. H., Joseph, R. W., Pal, S. K., Sznol, M., Hainsworth, J. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.431 · Cited by 70

Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR‐TKIs and mTOR inhibitor

Santoni, M., Berardi, R., Amantini, C., Burattini, L., Santini, D., Santoni, G., & Cascinu, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.28503 · Cited by 68

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

Powles, T. B., O’Donnell, P. H., Massard, C., Arkenau, H., Friedlander, T. W., Hoimes, C., Lee, J., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.286 · Cited by 68

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.

Hassan, R., Thomas, A., Patel, M. R., Nemunaitis, J. J., Bennouna, J., Powderly, J. D., Taylor, M. H., Dowlati, A., Chen, F., Leach, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.8503 · Cited by 67

Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.

Lara, P. N., Bauer, T. M., Hamid, O., Smith, D. C., Gajewski, T. F., Gangadhar, T. C., Somer, B. G., Schmidt, E. V., Zhao, Y., Gowda, H. N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4515 · Cited by 67

Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475).

Doi, T., Piha-Paul, S. A., Jalal, S. I., Mai-Dang, H., Saraf, S., Koshiji, M., Csiki, I., & Bennouna, J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.7 · Cited by 64

Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

Smith, D. C., Gajewski, T. F., Hamid, O., Wasser, J. S., Olszanski, A. J., Patel, S. P., Mamtani, R., Schmidt, E. V., Zhao, Y., Maleski, J. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4503 · Cited by 63

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.

Chung, H. C., Arkenau, H., Wyrwicz, L. S., Oh, D., Lee, K., Infante, J. R., Lee, S. S., Lee, J., Keilholz, U., Mita, A. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4009 · Cited by 62

Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study

Balar, A. V., Joaquim Bellmunt, B., O’Donnell, P. H., Castellano, D., Grivas, P. D., Vuky, J., Powles, T. B., Plimack, E. R., Hahn, N. M., de Wit, R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw435.25 · Cited by 61

Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study

Mehnert, J. M., Rugo, H. S., O’Neil, B. H., Santoro, A., Schellens, J. H. M., Cohen, R., Doi, T., Ott, P. A., Pishvaian, M. J., Puzanov, I. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx368 · Cited by 56

A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).

Bendell, J. C., Bang, Y., Chee, C. E., Ryan, D. P., McRee, A. J., Chow, L. Q. M., Desai, J., Wongchenko, M. J., Yan, Y., Pitcher, B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.560 · Cited by 54

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

Deng, Y., Liu, W., Lian, Z., Li, X., & Hou, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9438 · Cited by 53

OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies

Quispel-Janssen, J. M. M. F., Zago, G., Schouten, R. D., Buikhuisen, W. A., Monkhorst, K., Thunissen, E., & Baas, P. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.300 · Cited by 53

Cell death and thymic tolerance

Daley, S. R., Teh, C. E., Hu, D. Y., Strasser, A., & Gray, D. H. D. (2017) · Immunological Reviews · doi:10.1111/imr.12532 · Cited by 52

Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC).

Fleming, G. F., Emens, L. A., Eder, J. P., Hamilton, E. P., Liu, J. F., Liu, B., Molinero, L. L., Fassò, M., O'Hear, C. E., & Braiteh, F. S. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5585 · Cited by 51

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

Scherpereel, A., Mazières, J., Greillier, L., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., Molinier, O., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.18_suppl.lba8507 · Cited by 50

Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study

Cottu, P. H., D’Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P., Duhoux, F. P., Lévy, C., Mouret-Reynier, M.-A., Dalenc, F., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440 · Cited by 50

Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028.

Varga, A., Piha-Paul, S. A., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Morosky, A., Zhao, G. Q., Rangwala, R. A., & Matei, D. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5513 · Cited by 49

PD-1 /PD-L1 checkpoint in hematological malignancies

Annibali, O., Crescenzi, A., Tomarchio, V., Pagano, A., Bianchi, A., Grifoni, A., & Avvisati, G. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.01.014 · Cited by 49

Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.

Ribas, A., Hodi, F. S., Lawrence, D. P., Atkinson, V. G., Starodub, A., Carlino, M. S., Fisher, R. A., Long, G. V., Miller, W. H., Huang, Y., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3014 · Cited by 47

Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.

Burgess, M. A., Bolejack, V., Tine, B. A. V., Schuetze, S. M., Hu, J. S., D’Angelo, S. P., Attia, S., Priebat, D. A., Okuno, S. H., Riedel, R. F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.11008 · Cited by 40

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC).

Hahn, N. M., Powles, T. B., Massard, C., Arkenau, H., Friedlander, T. W., Hoimes, C. J., Lee, J., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4525 · Cited by 40

A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.

Apolo, A. B., Mortazavi, A., Stein, M. N., Pal, S. K., Davarpanah, N. N., Parnes, H. L., Ning, Y. M., Francis, D. C., Cordes, L. M., Monk, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.293 · Cited by 39

First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.

Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F. C., Martignoni, M., Nathan, P., Powles, T. B., McDermott, D. F., Robbins, P. B., Chism, D. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4504 · Cited by 39

Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.

Chung, H. C., Arkenau, H., Wyrwicz, L. S., Oh, D., Lee, K., Infante, J. R., Chin, K. M., von Heydebreck, A., Kang, Y., & Safran, H. P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.167 · Cited by 38

KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer

Wainberg, Z. A., Jalal, S. I., Muro, K., Yoon, H. H., Marcelo Garrido, S., Golan, T., Doi, T., Catenacci, D. V. T., Geva, R., Ku, G. Y., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.020 · Cited by 36

Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology.

Diaz, L. A., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Azad, N. S., Dauses, T., Laheru, D. A., Lee, J. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3003 · Cited by 35

OA13.02 Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis

Kindler, H. L., Karrison, T. G., Tan, Y. C., Rose, B., Ahmad, M. I., Straus, C. M., Sargis, R. M., & Seiwert, T. Y. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.301 · Cited by 34

Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.

Gubens, M. A., Sequist, L. V. D., Stevenson, J. P., Powell, S. F., Villaruz, L. C., Gadgeel, S. M., Langer, C. J., Patnaik, A., Borghaei, H., Jalal, S. I., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9027 · Cited by 34

Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.

Dummer, R., Arance, A. M., Hansson, J., Larkin, J., Long, G. V., Gasal, E., Kaper, M., Upalawanna, A., Mookerjee, B., & Atkinson, V. G. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.189 · Cited by 34

Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma

Zhao, Q., Guo, J., Wang, G., Chu, Y., & Hu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.13774 · Cited by 33

An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).

Delord, J., Hollebecque, A., de Boer, J. P., Grève, J. D., Machiels, J., Leidner, R. S., Ferris, R. L., Rao, S., Soumaoro, I., Cao, Z. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.6025 · Cited by 31

Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study

Zandberg, D. P., Algazi, A. P., Jimeno, A., Good, J., Fayette, J., Bouganim, N., Ready, N., Clement, P., Goswmi, T., Jarkowski, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx374 · Cited by 31

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)

Gettinger, S. N., Chow, L. Q. M., Borghaei, H., Shen, Y., Harbison, C. T., Chen, A. C., & Rizvi, N. A. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.08.210 · Cited by 30

A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma.

Makker, V., Rasco, D. W., Dutcus, C. E., Stepan, D. E., Li, D., Schmidt, E. V., Shumaker, R. C., & Taylor, M. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5598 · Cited by 30

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy

Tazzari, M., Negri, T., Rini, F., Vergani, B., Huber, V., Villa, A., Dagrada, G. P., Colombo, C., Fiore, M., Gronchi, A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.437 · Cited by 29

Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.

Wainberg, Z. A., Höchster, H. S., George, B., Gutierrez, M. E., Johns, M. E., Chiorean, E. G., Kwak, E. L., Kalyan, A., Manax, V. G., Ye, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.412 · Cited by 29

REGN2810: A fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.

Papadopoulos, K. P., Owonikoko, T. K., Johnson, M. L., Braña, I., Gil-Martín, M., Perez, R. P., Moreno, V., Salama, A. K. S., Calvo, E., Yee, N. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9503 · Cited by 27

Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).

Chau, I., Bendell, J. C., Calvo, E., Santana-Dávila, R., Rodon, J. A., Penel, N., Arkenau, H., Yang, J., Rege, J. M., Mi, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.102 · Cited by 26

Durvalumab and tremelimumab in metastatic breast cancer (MBC): Immunotherapy and immunopharmacogenomic dynamics.

Santa-Maria, C. A., Kato, T., Park, J. H., Flaum, L., Jain, S., Tellez, C., Stein, R. M., Shah, A. N., Gross, L., Uthe, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3052 · Cited by 26

Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts).

Gadgeel, S. M., Ventimiglia, J., Kalemkerian, G. P., Fidler, M. J., Chen, W., Sukari, A. W., Halmos, B., Boerner, J. L., Wozniak, A. J., Galasso, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.8504 · Cited by 26

Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results

Bahleda, R., Braiteh, F. S., Balmanoukian, A. S., Braña, I., Hodi, F. S., Garbo, L. E., Liu, B., Molinero, L. L., O'Hear, C. E., Shen, X., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx374.001a · Cited by 25

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States

Pal, S. K., Hoffman-Censits, J. H., Zheng, H., Kaiser, C., Tayama, D., & Joaquim Bellmunt, B. (2018) · European Urology · doi:10.1016/j.eururo.2018.02.010 · Cited by 25

A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.

Duffy, A. G., Makarova‐Rusher, O. V., Pratt, D. W., Kleiner, D. E., Fioravanti, S., Walker, M., Carey, S., Figg, W. D., Steinberg, S. M., Anderson, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.560 · Cited by 24

PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.

Tykodi, S. S., Brahmer, J. R., Hwu, W., Chow, L. Q. M., Topalian, S. L., Hwu, P., Odunsi, K. O., Camacho, L. H., Kauh, J. S. W., Pitot, H. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2510 · Cited by 24

KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer

Daniel, V. C., Wainberg, Z. A., Charles, S. F., Marcelo Garrido, S., Bang, Y., Muro, K., Savage, M. J., Wang, J., Koshiji, M., Rita, P. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx302.008 · Cited by 24

Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.

Papadopoulos, K. P., Owonikoko, T. K., Johnson, M. L., Braña, I., Gil-Martín, M., Perez, R. P., Moreno, V., Salama, A. K. S., Calvo, E., Yee, N. S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.195 · Cited by 24

Cuproptosis: mechanisms and links with cancers

Xie, J., Yang, Y., Gao, Y., & He, J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01732-y · Cited by 843

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Wang, Z., Cui, C., Yao, J., Zhang, Y., Li, M., Feng, J., Yang, S., Fan, Y., Shi, J., Zhang, X., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.007 · Cited by 559

Application of PD-1 Blockade in Cancer Immunotherapy

Wu, X., Gu, Z., Yang, C., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 541

Signal pathways of melanoma and targeted therapy

Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 419

Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment

Marzagalli, M., Ebelt, N. D., & Manuel, E. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.002 · Cited by 358

Cancer Immunotherapy Beyond PD1/PD-L1

Dr. D. Rama Bramha Reddy, K. M. (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.21927064

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Gong, J., Chehrazi‐Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,307

Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development

Oliveira, L. J. D. C., Gongora, A. B. L., & Jardim, D. L. F. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00928-5 · Cited by 19

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

Abaza, A., Sid Idris, F., Anis Shaikh, H., Vahora, I., Moparthi, K. P., Al Rushaidi, M. T., Muddam, M. R., Obajeun, O. A., Jaramillo, A. P., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.44582 · Cited by 59

Overview of PD-1 and PD-L1 Inhibitors

Andreatos, N., Bhatia, S., & Grivas, P. D. (2019) · Springer Publishing Company eBooks · doi:10.1891/9780826172150.0002